Table 1 Clinicopathological characterization of patients included in the training datasets
Variable | Group | P value | ||
|---|---|---|---|---|
Active immune (n = 153) | Exhausted (n = 74) | Non-immune (n = 64) | ||
Age | 48.86 (14.29) | 47.31 (14.00) | 47.17 (12.43) | 0.611 |
BMI | 28.54 (8.52) | 27.60 (6.32) | 26.92 (5.97) | 0.366 |
Smoke | 0.852 | |||
Yes | 32 (20.9%) | 19 (25.7%) | 12 (18.8%) | |
No | 101 (66.0%) | 46 (62.2%) | 45 (70.3%) | |
Unknown | 20 (13.1%) | 9 (12.2%) | 7 (10.9%) | |
HPV state | 0.002 | |||
Positive | 147 (96.1%) | 70 (94.6%) | 53 (82.8%) | |
Negative | 6 (3.9%) | 4 (5.4%) | 11 (17.2%) | |
HPV16/18 state | < 0.001 | |||
Positive | 107 (69.9%) | 42 (56.8%) | 39 (60.9%) | |
Negative | 45 (29.4%) | 32 (43.2%) | 13 (20.3%) | |
Unknown | 1 (0.7%) | 0 (0.0%) | 12 (18.8%) | |
Clinical stage | 0.121 | |||
Stage I | 84 (54.9%) | 32 (43.2%) | 43 (67.2%) | |
Stage II | 35 (22.9%) | 18 (24.3%) | 11 (17.2%) | |
Stage III | 23 (15.0%) | 13 (17.6%) | 5 (7.8%) | |
Stage IV | 7 (4.6%) | 9 (12.2%) | 5 (7.8%) | |
Unknown | 4 (2.6%) | 2 (2.7%) | 0 (0%) | |
Lymph node state | 0.289 | |||
Yes | 95 (62.1%) | 37 (50.0%) | 42 (65.6%) | |
No | 22 (14.4%) | 11 (14.9%) | 8 (12.5%) | |
Unknown | 36 (23.5%) | 26 (35.1%) | 14 (21.9%) | |
Radiation therapy | 0.931 | |||
Yes | 77 (50.3%) | 35 (47.3%) | 31 (48.4%) | |
No | 31 (20.3%) | 13 (17.6%) | 12 (18.8%) | |
Unknown | 45 (29.4%) | 26 (35.1%) | 21 (32.8%) | |
Pathological type | < 0.001 | |||
Squamous | 150 (98.0%) | 73 (98.6%) | 18 (28.1%) | |
Adenosquamous | 0 (0.0%) | 1 (1.4%) | 3 (4.7%) | |
Adenocarcinoma | 3 (2.0%) | 0 (0.0%) | 43 (67.2%) | |